Fig. 1

In vitro cell viability assays testing adagrasib and abemaciclib combinatorial treatment. A, Table representing the characteristics of the two cell lines [1]. B, C, CellTiter-Glo and CyQUANT assays to evaluate cell viability and proliferation, respectively, with adagrasib (72 h drug exposure) and abemaciclib (120 h drug exposure) monotherapies in SW1573 cells B and H2122 cells C. SW1573 cells, adagrasib IC50: 4,027 nM and abemaciclib IC50: 833 nM. H2122 cells, adagrasib IC50: 21.2 nM and abemaciclib IC50: 626 nM. D, E, Combenefit software analysis testing synergism of combining adagrasib and abemaciclib using Highest Single Agent model analysis in SW1573 D and H2122 E cell lines (96 h drug exposure)